ERBB2 and breast cancer: However, the lower ORR of trastuzumab in HER2-positive gastric cancer than that of HER2-positive breast cancer prompted us to investigate the potential mechanisms that could provide novel strategies for trastuzumab therapy in HER2-positive gastric cancer.